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ABSTRACT 
Background: Positron emission tomography using [methyl-11C]-choline is 
effective in imaging many types of cancer, especially prostate cancer (PC). The 
antiandrogen flutamide is often used as part of the initial treatment of PC. Data 
on the effect of flutamide on and methylcholine incorporation i to PC-3 cells are 
lacking in the experimental nd literature work. 
Objectives: The aims of this study were to assess whether human PC-3 cells 
are susceptible to flutamide and whether the drug modulates the uptake of 
[methyl-3H]-choline i to these cells. 
Methods: PC-3 cells were treated for 3 days with flutamide (_<100 nmol/L), 
inhibiting growth by 20% to 70% with control cells included. Two viability tests 
(cytotoxic analyses), the thiazole blue assay and the trypan blue exclusion 
method, were used to determine the median inhibitory concentration for flu- 
tamide (10 nmol/L). Control and flutamide-treated cells were incubated with 
[methyl-3H]-choline for10 minutes and then in nonradioactive medium for 10 min- 
utes to simulate the rapid blood clearance of [methyl-11C]-choline tracer that 
occurs within 5 to 20 minutes, and then extracted using organic and aqueous ol- 
vents to determine the intracellular distribution of the tracer. Protein assay and 
flow-cytometry analysis were used to determine protein content and DNA synthe- 
sis in both control and treated cells. The uptake of [methyl-3H]-choline was nor- 
malized to protein content and expressed as mean (SD) dpm/1Jg protein (n = 6). 
Results: PC-3 cell proliferation was inhibited with flutamide treatment. After 
treatment of PC-3 cells with flutamide 10 nmol/L for 3 days, cells accumulated 
DNA during the S phase. Mean (SD) [methyl-3H]-choline uptake was found to be 
significantly lower with flutamide 10-nmol/L-treated cells compared with con- 
trol cells (65.95 [0.72] vs 114.21 [0.57] dpm/1Jg protein; P< 0.001); the difference 
between the 5-nmol/L-treated cells and controls was nonsignificant. 
Conclusions: In this pilot study, flutamide inhibited tumor cell growth and 
proliferation and decreased (modulated) the uptake of [methyl-3H]-choline i to 
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androgen receptor-negative PC-3 cells. These results suggest hat flutamide 
might inhibit proliferation by an androgen-independent mechanism. (Curr Ther 
Res Clb~ Exp. 2007;68:226-241) Copyright © 2007 Excerpta Medica, Inc. 
Key words: flutamide, tumor, PET, radiopharmaceuticals, [methyl-3H]-choline, 
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INTRODUCTION 
Studies suggest hat changes in the uptake of positron emission tomography 
(PET) tracers (eg, 18F-2-fluoro-2-deoxy-D-glucose [18F-FDG] and 18F-fluorothymidine 
[18F-FLT]) in cancer cells from before to after chemotherapy 1,2 and radiotherapy 3,4
indicate the efficacy of cancer treatments and can be used for predicting the 
response of the tumor to treatment. PET with 18F-FDG is widely used for detect- 
ing nonprostate cancers uch as breast cancer and colorectal cancer and manag- 
ing cancer treatment, s-7 However, this imaging method has not been found to be 
useful for detecting prostate cancer (PC) because of excessive radionuclide 
excretion in the urine, which masks lesions in the lower pelvic region, s 
Recently in 1997-1998, [methyl-11C]-choline was introduced as a marker in PC 
imaging because of its negligible urinary activity and high uptake in tumor 
cells. 9,1° PET with [methyl-11C]-choline has also been used to assess the effec- 
tiveness of treatments for localized PC. 11 Assessing the efficacy of PC treatment 
is currently based largely on posttreatment serum levels of prostate-specific 
antigen (PSA). 12,13 An increase in PSA level 0e, biochemical recurrence) is the 
first sign of recurrent disease and can precede a clinically detectable recur- 
rence by months or years. Digital rectal examination and conventional imaging 
techniques are in some cases not sufficiently sensitive to detect localized recur- 
rences of PC. Thus, a metabolic imaging technique that does not depend on 
anatomic hanges might be useful in assessing treatments for localized PC. 
De Jong et a111 found that the site of localized PC recurrence was detected 
correctly (true positive) using PET with [methyl-11C]-choline  78% of patients 
after external beam radiotherapy (n = 16) compared with 38% of patients after 
radical prostatectomy (n = 20). No positive PET scan results were observed in 
patients whose serum PSA level was <5 ng/mL. Those results suggest hat PET 
with [methyl-11C]-choline is a promising and noninvasive metabolic imaging 
technique to image and assess treatments for localized PC. 9,11 
Currently available hormonal and chemotherapeutic strategies have had lim- 
ited success in controlling PC. 14 This is because PC tumors consist of both 
androgen-sensitive c lls (eg, LNCaP and C4-2) and hormone-independent, 
androgen-insensitive cells (eg, PC-3), which differ in their responses to the thera- 
peutic strategies. Normal prostatic growth is regulated by growth hormone, 
estradiol, d ihydrotestosterone (DHT), and testosterone. Flutamide, a pure 
antiandrogen, prevents the interaction of testosterone and DHT with androgen 
receptors (ARs) in PC cells. In the presence of a ligand (eg, DHT), the AR is acti- 
vated, resulting in stimulation or inhibition of gene transcription, which is mod- 
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erated by steroid hormones. 15Flutamide is often used as part of the initial treat- 
ment of PC. 16'17 
We previously reported that the uptake of [methyl-3H]-choline into breast 
tumor (MCF-7) cells correlated strongly with proliferation, as determined by 
[methyl-14C]-thymidine uptake. 18 Chemotherapy induced the modulation of 
[methyl-3H]-choline uptake in MCF-7 cells treated with 5-fluorouracil in certain 
mechanisms. Data on the effect of flutamide on and methylcholine incorporation 
into PC-3 cells are lacking in the experimental nd literature work. The objec- 
tives of this study were to assess whether flutamide lyses human PC-3 cells 
and/or modulates the uptake of [methyl-3H]-choline i to these cells. 
MATERIALS AND METHODS 
This pilot study was conducted at the Nuclear Medicine Department, Kuwait 
University Health Sciences Center, Safat, Kuwait. The study protocol was 
approved by the center's institutional review board and conducted in accor- 
dance with the Declaration of Helsinki and its amendments. 19 
Human PC-3 cells were obtained from the American Type Culture Collection, 
Manassas, Virginia. The radiolabeled compound [methyl-3H]-choline chloride 
(specific activity, 2.92 TBq/mmol) was obtained from Amersham Pharmacia 
Biotech UK, Ltd., Buckinghamshire, United Kingdom. All chemical reagents 
used were supplied by Sigma-Aldrich Company, Dorset, United Kingdom, unless 
otherwise specified. Ultima gold scintillant fluid was obtained from Meridian, 
Scotland, United Kingdom. Culture flasks and 96-well plates were obtained from 
Nunc A/S, Roskilde, Denmark. 
Cell Culture and Cell Media 
PC-3 androgen-sensitive (active treatment) and androgen-insensitive wild- 
type cells (control group) were grown in Dulbecco's Modified Eagles medium 
(DMEM) supplemented with penicillin 20 U/mL, streptomycin 20 1Jg/mL, and 
10% fetal calf serum. All cells were cultured in monolayers in 25-cm 2 flasks in 
triplicate, incubated at 37°C (in 5% CO2:95% air), and allowed to grow exponen- 
tially to 70% confluence. 
Drug Dose and Choline Uptake 
PC-3 cells were treated with flutamide 0(untreated or control), 5, or 10 nmol/L 
added to 25-cm 2 flasks in triplicate and incubated for 3 days. 
[Methyl-3H]-Choline Pulse-Chase and Efflux 
Control and treated cells were incubated in triplicate for 10 minutes at 37°C 
with 37 kBq of [methyl-3H]-choline/mL DMEM in 25-cm 2 flasks, washed 6 times 
with 0°C phosphate-buffered saline (PBS), then incubated with nonradioactive 
DMEM for 10 minutes. The cells were then washed once with 0°C PBS, 
trypsinized with 0.5 mL trypsin neutralized with 0.5 mL medium, and cen- 
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trifuged at 10,000g for 5 minutes at 4°C. Radioactivity in the media was counted 
using a liquid scintillation counting analyzer (Packard TriCARB LSC-1900CA, 
Packard Instrument Company, Frankfurt, Germany). Cell pellets were washed 
once with PBS to remove xtracellular protein, and the intracellular location of 
[methyl-3H]-choline was determined using extraction with organic and aqueous 
solvents. The uptake of [methyl-3H]-choline was normalized to protein content 
and expressed as mean (SD) dpm/1Jg protein (n = 6). 
Extraction of Radiolabeled Metabolites and Lipids 
Metabolites were extracted from control and treated cells using a chloroform/ 
methanol Tris buffer solvent system. 2° Cells were pelleted in Eppendorf tubes 
(Eppendorf AG, Hamburg, Germany) to which 1 mL of methanol and 0.5 mL 
of chloroform were added, and allowed to stand at 4°C for 1 hour. Then 0.5 mL 
of chloroform was added, followed by 0.5 mL of Tris buffer (10 mM; pH 7.0), 
and the contents were thoroughly mixed. After centrifugation at 1000g for 
15 minutes at 4°C, the upper (aqueous) and lower (lipid) phases eparated, and 
the radioactivity of a sample of each was counted. Protein assay content was 
determined on the cell debris located at the interface of the 2 phases using 
standards prepared from a solution of 1.4 mg/mL bovine serum albumin after 
solubilization with 1 M NaOH and neutralization with HC1. 
Cell-Viability Assay 
Cell viability was assessed using both the 3-[4,5-dimethylthiazol-2-yl]- 
2,5-diphenyl tetrazolium bromide salt (also called thiazole blue [MTT]) assay 
and the trypan blue (TB) exclusion method. 
Thiazole Blue Assay 
Cells were seeded in flat-bottomed, 96-well tissue culture plates at a concen- 
tration of 1 × 105 cells/mL medium at 200 1JL/well and were allowed to grow to 
70% confluence before flutamide was added. The plates were set up for controls 
and flutamide _<100-nmol/L concentrations and were then incubated in a humidi- 
fied atmosphere with 5% CO2:95% air at 37°C. After reaching 70% confluence, 
flutamide _<100 nmol/L was added separately to triplicate plates of PC-3 cells 
and incubated for 3 days. Subsequently, the medium was removed using a 
pipette, and new medium of 170 1JL/well was added. Then 301JL of MTT (5 mg/mL 
in PBS) was added to each well, and incubation of the cells continued. After 
4 hours, the medium was removed using a pipette, leaving the adherent cells 
and precipitate in the wells. Then 200 1JL of dimethyl sulfoxide was added to 
each well and the solution was gently mixed for 20 minutes to dissolve the pre- 
cipitate, and the appearance of the crystals was observed under an Olympus 
light microscope (X400, model 1X70-S8F2, Olympus Optical Co. Ltd., Tatsuno, 
Japan). The plates were then read in a 96-well plate scanner (enzyme-linked 
immunosorbent assay kit; Microplate Reader Model 450; Bio-Rad Laboratories, 
Inc., Munich, Germany) at dual-filter wavelengths of 540 and 690 nm. 
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Trypan Blue Exclusion Method 
The main aim of this study was to assess whether human PC-3 cells are sus- 
ceptible to flutamide or whether flutamide kills human PC-3 cells or not. Our 
secondary objectives were to investigate the effect of flutamide on choline 
uptake and to determine whether [methyl-11C]-choline PET could provide use- 
ful clinical information. In another set of experiments, PC-3 wild-type cells were 
grown to 70% confluence in 25-cm 2flasks in triplicate, followed by the addition 
of flutamide 0 (untreated), 5 or 10 nmol/L for 3 days. To prevent viable cells 
from absorbing the stain, the stain was diluted just before viable cells were 
counted, thereby making the cells appear nonviable. Cells were harvested by 
trypsinization, eutralized with medium, and washed with PBS. TB was added 
to suspended cells at a concentration of 0.4% weight/volume for 3 to 5 minutes. 
The number of live cells was determined using a Neubauer hemocytometer 
(Sigma-Aldrich, St. Louis, Missouri) and expressed as a percentage of the con- 
trois. In the cells treated with flutamide ~100 nmol/L, these viability tests were 
used for determining the optimum concentration and median inhibitory con- 
centration (ICs0) of flutamide to be used in the subsequent [methyl-3H]-choline 
uptake experiments. In the viability tests, cells treated with flutamide 5 and 
10 nmol/L were found to be 75% and 50% viable, respectively (control cells were 
100% viable). For comparison, control cells and those treated with flutamide 
5 nmol/L were used in addition to those treated with the ICs0 (10 nmol/L). 
Control and treated PC-3 cells were incubated in 25-cm 2 flasks with (1 1JCi) 
37 kBq/mL medium per flask of [methyl-3H]-choline i  triplicate for 10 minutes at 
37°C. Pulse-chase and efflux method, protein assay, and flow cytometry were per- 
formed in control and treated cells. 
Flow Cytometry 
Another set of control and treated cells was used for flow-cytometry analy- 
sis. Control and treated cells harvested using trypsinization were washed twice 
in 0°C PBS and resuspended in 100 pL of PBS. One milliliter of ice-cold 70% 
ethanol was added to the cell suspension during centrifugation, and the cells 
were let stand overnight at -20°C. Prior to flow-cytometry analysis, the number 
of cells was adjusted to 1 × 106 cells/sample. One milliliter of PI/RNAse and tri- 
ton ×-100 staining buffer was added to the cells, and the suspension was incu- 
bated for 20 minutes at 20°C while protected from light. Flow cytometry was 
performed using 488-nm laser light on a FACSCalibur flow cytometer (Becton, 
Dickinson and Company, Franklin Lakes, New Jersey) and CELLQuest software 
(Becton, Dickinson and Company) equipped for fluorescence detection, for- 
ward 90°-angle light scatter, and doublet discrimination. 
Statistical Analysis 
All data are expressed as mean (SD) of the mean of at least 3 measurements. 
The t test (paired) was used to determine statistical differences between the 
control and treated means. 
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RESULTS 
Cell V iab i l i ty  Assays 
Figure 1 shows nonlinear regression of the treatment effect, viability, and IC~ 0 
for flutamide on PC-3 cells using MTT (%MTT) (n = 12) and TB (%TB) (n = 3) 
tests compared with controls. 
Drug Dose and [methyl -3H]-Chol ine Uptake  
Fig.re 2 shows DNA histograms of PC-3 cells incubated with flutamide and 
controls for 3 days. Accumulation of DNA in the S (DNA-synthesis) phase of 
PC-3 cells was induced after incubation with flutamide 10 nmol/L. 
Table I shows [methyl-3H]-choline uptake (n = 6) and corresponding S phases 
(n = 3) of PC-3 cells after exposure to flutamide 5 or 10 nmol/L for 3 days 
and control cells. Mean (SD) total [methyl-3H]-choline uptake in cells treat- 
ed with flutamide 5 nmol/L was similar to that in controls (93.98 [0.97] vs 
114.21 [0.57] dpm/pg protein) but significantly lower in those treated with 
10 nmol/L (65.95 [0.72] dpm/pg protein; P < 0.001 vs controls). Cell accumulation 
of DNA in the S phase was significantly higher in the cells treated with flutamide 
10 nmol/L compared with that in controls (61.81 [1.33] vs 30.03 [0.58]; P < 0.001). 
Table II shows the mean (SD) [methyl-3H]-choline radioactivity of the upper 
(aqueous) and lower (lipid) phases (n = 6). The mean (SD) [methyl-3H]-choline 
radioactivity of the lipid phases were significantly higher in the cells treated 
with flutamide 5 and 10 nmol/L compared with that in controls (34.98 [6] and 
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Figure 1. Nonlinear regression showing the results of the viability tests using the thia- 
zole blue (MTT) assay and the trypan blue (TB) exclusion method after 
prostate cancer-3 cells were exposed to flutamide for 3 days. (Cell viability 
is expressed as mean [SD] of the values obtained from 12 replications with 
MTT and 3 with TB using 96-well plates.) 
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Figure 2. DNA histograms of phases G1, S, and G 2 for prostate cancer-3 cells (A) alone 
and (B) when incubated with flutamide 10 nmol/L for 3 days. 
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Table I. [Methyl-3H]-choline uptake and corresponding S-phase values for prostate 
cancer-3 cells after exposure to flutamide. Values are mean (SD). 
Flutamide Flutamide 
Parameter 5 nmol/L 10 nmol/L Control 
Choline uptake, 
dpm/IJg protein 
(n = 6) 93.98 (0.97) 65.95 (0.72)* 114.21 (0.57) 
s Phase, 
dpm/IJg protein 
(n = 3) 30.54 (0.30) 61.81 (1.33)* 30.03 (0.58) 
*P < 0.001 versus control. 
Table II. [Methyl-3H]-choline radioactivity of the aqueous (upper) and lipid (lower) 
phases. Values are mean (SD). 
Flutamide Flutamide 
Parameter 5 nmol/L 10 nmol/L Control 
Aqueous, 
dpm/iJg protein 60.02 (11)* 52.24 (16)* 85.02 (5) 
Lipid, 
dpm/iJg protein 34.98 (6)* 47.76 (12)* 14.98 (4) 
*P < 0.001 versus control. 
47.76 [ 12] vs 14.98 [4] dpm/1Jg protein; P < 0.001). Also the aqueous phases were 
significantly higher in the cells treatment with flutamide 5 and 10 nmol/L com- 
pared with that in controls (60.02 [11] and 52.24 [16] vs 85.02 [5] dpm/1Jg pro- 
tein; P < 0.001). 
DISCUSSION 
[Methyl-11C]-choline was introduced in 1997 to 1998 as a tumor-seeking PET 
tracer, 9,1° especially for imaging and staging PC. 11'21'22 We found decreased cell 
viability and an accumulation of DNA in cells in the S phase of the cell cycle in 
PC-3 cells treated with flutamide using [methyl-UC]-choline tracer. 
At the onset of cancer progression, primary tumors are composed predomi- 
nantly of androgen-insensitive cells (ie, cell growth and proliferation are not af- 
fected by antiandrogen drugs or by androgen deprivation). 23 However, PC tumors 
consist of both androgen-sensitive cells (eg, LNCaP and C4-2) and hormone- 
independent, androgen-insensitive cells (eg, PC-3). Thus, currently available hor- 
monal and chemotherapeutic drugs have limited success in controlling PC and 
its progression. 14PC-3 cells lack functional ARs24; that is, any ARs they might 
contain are expressed at low levels and respond neither to androgens nor 
antiandrogens, and the growth and proliferation of the cells are unaffected. 23,25-28 
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Thus, PC-3 cells have been used extensively as a model for androgen-independent/ 
insensitive and hormone-independent/nonresponsive PC tudies. In the present 
preliminary study, we used androgen-insensitive wild-type PC-3 cells as con- 
trois to investigate the effects of flutamide and found that PC-3 cells were 
lysed with flutamide treatment, which was unexpected. Therefore, our second- 
ary objectives were to investigate the effect of flutamide on choline uptake and 
to determine whether [methyl-11C]-choline PET could provide useful clinical 
information. 
As mentioned, the present study found that flutamide was associated with 
the inhibition of cell proliferation i  PC-3 cells; this inhibition was likely associ- 
ated with an accumulation of DNA in cells in the S (DNA-synthesis) phase and a 
dose-dependent decrease in [methyl-3H]-choline uptake. Flutamide, a pure anti- 
androgen, has been found to prevent he interaction of testosterone and DHT 
with ARs on prostate cells. 26,29,3° After incubating PC-3 cells in flutamide for 
3 days, the ICs0 was found to be 10 nmol/L, suggesting a relationship between 
flutamide and cell proliferation and its modulation to choline uptake. Also, this 
cell proliferation i hibition suggests that choline metabolites and phospholipid 
synthesis were affected by flutamide by a mechanism other than the well- 
known AR mechanism in PC-3 cells. Based on this modulation to choline uptake, 
we can investigate other mechanisms of choline uptake into tumor cells. This 
investigation can also be useful in determining choline DNA accumulation dur- 
ing the clinical imaging time of [methyl-11C]-choline PET scans. The decreased 
uptake might be related to a decrease in phospholipid synthesis and the recy- 
cling of phospholipids or to choline metabolite content in the aqueous phase. 
In the present study, there was an increase in lipid choline uptake associated 
with S-phase accumulation, suggesting that choline causes cell proliferation. 
Studies suggest that [methyl-11C]-choline used during PET might accumulate in
tumor cells via increased phospholipid synthesis and phosphocholine (PCho) 
trapping with highly proliferating cells. 31,32 Hara 31 suggested that the only meta- 
bolic fate of [methyl-11C]-choline s conversion into PCho within tumor cells and 
integration into phospholipids, resulting in the production of phosphatidyl- 
choline (PtdCho). Once [methyl-11C]-choline has been phosphorylated within 
tumor cells, it remains there, yielding 11C-PCho and constituting a chemical 
"trap." Hara also suggested that [methyl-11C]-choline might be useful for indi- 
cating the rate of membrane synthesis and, therefore, the rate of replication of 
tumor cells. 
The results of this preliminary study are encouraging; however, the study 
had many limitations, such as the need for new flow-cytometry techniques to 
determine the relationship between specific stages of the cell cycle and apop- 
tosis. Another limitation was the need to study hormonal receptors more care- 
fully in PC-3 cells and also to study alternative mechanisms of action of flu- 
tamide, including investigating additional concentrations and study durations 
(ie, 1 or 2 days after cell treatment). Additional PC cell lines should also be 
investigated, and in vivo studies carried out in parallel to assess other non- 
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tumor and hormonal factors such as growth hormone, calcitonin, and hypoxic 
tissue. 
A reduction in choline uptake after treatment has been reported 33,34 DeGrado 
et a134 reported that fluorocholine PET uptake, which closely mimics choline 
uptake by normal tissues and PC cells, was markedly reduced in patients re- 
scanned uring androgen-deprivation treatment. The results from the present 
study of PC-3 cells incubated in flutamide suggest hat flutamide acts by a 
mechanism other than the well-known mechanism ofpreventing the interaction 
of testosterone and DHT with ARs in the prostate. This mechanism, which 
inhibits cell growth and proliferation, might occur in several ways. Inaloz et a135 
found that flutamide administration i  rats was associated with inhibited skin 
growth and proliferation i  parallel with a decrease in the production of epider- 
mal growth factor (EGF), a key hormone for skin development that is known to 
stimulate cell proliferation and differentiation i a wide range of tissues. The 
author's proposed model for such a mechanism is shown in Figure 3. Flutamide 
likely inhibits the action of growth factors uch as EGF in PC-3 cells, resulting in 
the inhibition of cellular proliferation and DNA synthesis and/or alteration of 
cellular phospholipid metabolism, and, subsequently, choline uptake in the PC-3 
cells. Flutamide likely inhibits the response of the EGF receptor to stimulatory 
agonists. 35-37 EGF increases diacylglycerol levels and activates phospholipase D 
(PLD)-catalyzed PtdCho breakdown, 38producing choline. EGF increases cell 
proliferation via elevated expression and activity of PLD isozymes in trans- 
formed fibroblasts, thereby overexpressing the EGF receptor. 39,4° Flutamide is 
likely involved in the inhibition of EGF function, resulting in the inhibition of 
PLD and ultimately in the inhibition of choline uptake and cell proliferation. In
addition, inhibition of protein kinase C (PKC) 41'42 results in the activation of 
mitogen-activated protein kinase (MAPK) and mitogenic extracellular kinase 
(MEK) pathways, together with their partner kinases. This kinases activation 
results in stimulation of the inhibitory function of retinoblastoma protein on cell- 
cycle progression 43and p53 expression, resulting in nuclear transcription fac- 
tors that inhibit cell proliferation. In addition, it has been found that the inhibi- 
tion of PCho production by hemicholinium-3 interferes with the activation of the 
Raf/MAPK pathway, 44 which is essential for cell proliferation. PLD and PKC acti- 
vation are involved in the hydrolysis and resynthesis of PtdCho, leading to the 
formation of second messengers, which are ultimately involved in altering phos- 
pholipid metabolism and decreasing [methyl-3H]-choline uptake in PC-3 cells. 
The results from our study are in agreement with those from the study by 
Montalvo et al, 45 who reported that flutamide potentiated the expression of 
4 PKC isozymes (c¢, 1~1, ~, ~) that are involved in cell growth, apoptosis, and neo- 
plastic transformation. The expression of PKC isozymes and the AR were ana- 
lyzed using Western blot and reverse-transcription polymerase chain reaction 
tests, respectively. No expression of AR was detected; thus, the effects of flu- 
tamide in PC-3 cells were likely independent of AR. These results provide evi- 
dence that flutamide may elicit responses in PC cells that do not express AR. 
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Another possible mechanism is mediated through estrogen receptors 
(ERs). 46,47 For example, Kawashima et a146 reported that in PC-3 cells, both cell 
growth and AR activity were remarkably significantly inhibited by tamoxifen 
50 1Jmol/L and flutamide 5 to 50 1Jmol/L. They also reported that  synthetic 
estrogen diethylstilbestrol and progesterone-related drugs, such as chlormadi- 
none acetate and allylestrenol, dose dependently inhibited AR activity in DU-145 
and PC-3 cells. They reported that antiestrogens modulated the transactivation 
activity of the ARs in PC cells. Although the most striking characteristic of PC 
is its androgen dependence, strogen seems to be involved. 48-5° In the human 
prostate, ERc¢ is localized in the stromal tissue and is associated with the pro- 
Flu 
PLD 
PKC 
I I 
~ 1  ~'~ ~ c-Raf-1 Cell 
MEK//APK / 
~CNuclear transcription factors I / 
DNA Synthesis I ~  ~ 
Figure 3. Proposed model for flutamide nonandrogen receptor action. EGF = epidermal 
growth factor; PLD = phospholipase D; PKC = protein kinase C; Ras-GTP = 
cellular as oncogenes coupled to guanosine triphosphate (GTP); c-Raf-1 = 
a serine/threonine protein kinase (family of protooncogenes); MEK/MAPK = 
mitogenic extracellular kinase/mitogen-activated protein kinase. 
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gression, metastasis, and hormone-refractory characteristic of PC. 49'51 Both 
ERc¢ and ER[~ have been found to be expressed in PC-3 cells. 52 The activation of 
ER[~ by its putative ligands 5c¢ androstane-3[~ and 171~-estradiol has been 
reported to be associated with suppression of ventral prostate growth. 53 
Activation of such receptors might be involved in inhibition of cell proliferation 
and subsequent choline uptake in PC-3 cells treated with flutamide. Also, flu- 
tamide could act via mechanisms similar to those involved in the inhibitory 
effect of tamoxifen (TAM) (the antiestrogen widely used in breast-cancer thera- 
py), which, although unclear at present, are thought o involve caspase activa- 
tion. The antiestrogen raloxifene has been reported to induce apoptosis in 
androgen-independent PC cells through caspase activation. 54TAM inhibits PC 
by inhibiting PKC, which is followed by the induction of the production of 
p21(waf1/cip1). 55 Kiss and Crilly 56 reported that in an ER-deficient, multidrug- 
resistant subline of MCF-7 human breast carcinoma cells (MCF-7/MDR), clini- 
cally relevant concentrations of TAM were associated with the inhibition of the 
uptake and phosphorylation f choline, and, as a result, the synthesis of corre- 
sponding phospholipids. In the present study, PC-3 cells treated with flutamide 
showed a dose-dependent reduction in [methyl-3H]-choline uptake, reflecting a
decrease in phospholipid synthesis. 
Flutamide induces apoptosis in PC-3 cells through the formation of free radi- 
cals, which inhibit the ability of cells to synthesize new DNA and ultimately 
reduce choline uptake. Nunez-Vergara et a157 studied the electrochemical char- 
acteristics and the reactivity of the 1-electron reduction product from flutamide 
in mixed media with thiol compounds and reported that flutamide was associ- 
ated with the formation of free radicals. Another study reported hypospermato- 
genesis in the offspring of adult male rats treated with flutamide, which might 
have been related to a chronic apoptotic process associated with a long-term 
increase in caspase-3 and -6 expression and activation in germ cells. 58 
The results of this pilot study might have clinical significance in terms of PC 
diagnosis, treatment, and radiologic monitoring, but further esearch is needed. 
The results of the present study suggest hat noninvasive imaging of PC using 
[methyl -11C]-choline PET scanning is a metabolic imaging technique that can be 
used to assess the uptake of choline according to the stage of cell proliferation 
and phospholipid synthesis before and after treatment and without he wait for 
or dependence on any anatomic alterations. Also, PET imaging might have an 
impact on treatment management because it might provide a sensitive measure 
between drug and mechanism of uptake (modulation). 
CONCLUSIONS 
In this pilot study, flutamide inhibited tumor cell growth and proliferation and 
decreased (modulated) the uptake of [methyl-3H]-choline i to AR-negative PC-3 
cells. These results suggest hat flutamide might inhibit proliferation by an 
androgen-independent mechanism. 
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